Observational studyClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Efficacy and Safety of the Individual Batroxobin Strategy in Treating Cerebral Venous Thrombosis: An Obstervational Study.
Observational study in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundPrevious studies have demonstrated the potential benefits of the routine use of batroxobin in treating cerebral venous thrombosis (CVT). However, there is still a need to discuss how to achieve maximum clinical effectiveness when using batroxobin for CVT correction. Therefore, this study aimed to analyze the efficacy and safety of individualized batroxobin strategies in treating CVT.MethodsThis observational clinical study analyzed data from 41 patients with acute CVT. The patients were divided into two groups based on their batroxobin treatment strategies: the individualized group (batroxobin used more than 5 times, n = 16) and the standard group (batroxobin used 3 times, n = 25). The degree of recanalization and attenuation of segmental stenosis were analyzed using MRBTI. The incidence of bleeding events was also analyzed.ResultsThe individualized group had significantly higher odds of achieving recanalization (14/16) [adjusted OR (95%CI) of 2.96 (1.30-6.71)] and greater attenuation of segmental stenosis [adjusted OR (95%CI) of 2.16 (1.04-4.49)] compared to the standard group (17/25). There was no statistically significant difference in the incidence of bleeding events between the individualized and standard groups (P > 0.05).ConclusionsThis observational study suggests that an individualized batroxobin strategy may be more effective than the standard approach in promoting cerebral venous thrombosis (CVT) recanalization and reducing CVT-induced stenosis. Further clinical trials are needed to confirm the potential benefits of this individualized therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.